Sanofi Announces Positive Phase III TEMSO Results
Sanofi and their subsidiary Genzyme announced the publication of their pivotal Phase III TEMSO (Teriflunomide Multiple Sclerosis Oral) study with investigational once-daily oral medication teriflunomide in The New England Journal of Medicine (NEJM). The results showed that teriflunomide, at the 14mg dosage, significantly reduced the yearly relapse rate, reduced disability progressions and improved numerous magnetic